The consumer health company also disclosed its CEO’s departure, following its CFO replacement earlier this year, and appointed an interim chief executive. Preliminary second-quarter 2025 results show ...

After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price ...

Johnson & Johnson ( NYSE: JNJ) Q2 2025 Earnings Conference Call July 16, 2025 8:30 AM ET ...

Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

Skillman, New Jersey-based Kenvue Inc. (KVUE) operates as a global consumer health company. Valued at $41.9 billion by market ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $23.58, a high estimate of $25.00, ...

Kenvue’s board of directors are considering ‘a broad range of potential alternatives’ and are hunting for a permanent ...

“The Board’s strategic review is underway, and we are considering a broad range of potential alternatives, including ways to ...